The Clinical Research Management Shared Resource (CRM) supports OHSU Knight Cancer Institute investigators in conducting translational, clinical and epidemiological research aimed at improving the lives of people and families with cancer by applying innovative strategies for cancer prevention, cancer treatment, and support of cancer survivors. The CRM provides training for new investigators, fellows, research nurses and clinical trial staff in the conduct of clinical trials. The CRM facilitates innovative and translational investigator-initiated Pilot/Phase I and small Phase II institutional protocols as part of Protocol Specific Research Support. This Shared Resource assists investigators in the preparation, conduct, and reporting of local, investigator-initiated studies. Prior to study initiation, the CRM offers investigators budget development and negotiation services as well as ongoing study account management. During conduct of a trial. Cancer Institute nurse researchers and experienced study coordinators use a team approach to provide investigators with all aspects of study coordination including safety monitoring and reporting. The CRM provides personnel management and oversight of research nurses and study coordinators.

Public Health Relevance

The Clinical Research Management Shared Resource (CRM) supports OHSU Knight Cancer Institute investigators in conducting translational, clinical and epidemiological research aimed at improving the lives of people and families with cancer by applying innovative strategies for cancer prevention, cancer treatment, and support of cancer survivors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-16
Application #
8504965
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
16
Fiscal Year
2013
Total Cost
$86,672
Indirect Cost
$23,262
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6
Li, Bingbing X; Chen, Jingjin; Chao, Bo et al. (2018) Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS Chem Biol 13:1380-1387
Hulett, Tyler W; Jensen, Shawn M; Wilmarth, Phillip A et al. (2018) Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J Immunother Cancer 6:27
Vranka, Janice A; Staverosky, Julia A; Reddy, Ashok P et al. (2018) Biomechanical Rigidity and Quantitative Proteomics Analysis of Segmental Regions of the Trabecular Meshwork at Physiologic and Elevated Pressures. Invest Ophthalmol Vis Sci 59:246-259
Lane, Ryan S; Lund, Amanda W (2018) Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors. Front Immunol 9:2662
Tyner, Jeffrey W; Tognon, Cristina E; Bottomly, Daniel et al. (2018) Functional genomic landscape of acute myeloid leukaemia. Nature 562:526-531
Risom, Tyler; Langer, Ellen M; Chapman, Margaret P et al. (2018) Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun 9:3815
Minnier, Jessica; Pennock, Nathan D; Guo, Qiuchen et al. (2018) RNA-Seq and Expression Arrays: Selection Guidelines for Genome-Wide Expression Profiling. Methods Mol Biol 1783:7-33
Su, Yulong; Pelz, Carl; Huang, Tao et al. (2018) Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev 32:1398-1419
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828

Showing the most recent 10 out of 277 publications